01 7Allelock
02 7Patanol
03 1Topical Olopatadine Group
04 2Topical Olopatadine Group
Main Therapeutic Indication : Immunology
Currency : USD
2020 Revenue in Millions : 101
2019 Revenue in Millions : 129
Growth (%) : -22
Main Therapeutic Indication : Immunology
Currency : USD
2020 Revenue in Millions : 82
2019 Revenue in Millions : 102
Growth (%) : -20
Main Therapeutic Indication : Immunology
Currency : USD
2021 Revenue in Millions : 90
2020 Revenue in Millions : 101
Growth (%) : 1
Main Therapeutic Indication : Immunology
Currency : USD
2021 Revenue in Millions : 68
2020 Revenue in Millions : 82
Growth (%) : -7
Main Therapeutic Indication : Immunology
Currency : USD
2022 Revenue in Millions : 45
2021 Revenue in Millions : 68
Growth (%) : -33
Main Therapeutic Indication : Immunology
Currency : USD
2022 Revenue in Millions : 21
2021 Revenue in Millions : 90
Growth (%) : -77
Main Therapeutic Indication : Immunology
Currency : USD
2023 Revenue in Millions : 37
2022 Revenue in Millions : 45
Growth (%) : -8
Main Therapeutic Indication : Immunology
Currency : USD
2023 Revenue in Millions : 13
2022 Revenue in Millions : 21
Growth (%) : -29
Main Therapeutic Indication : Anti-allergic
Currency : USD
2017 Revenue in Millions : 153
2016 Revenue in Millions : 175
Growth (%) : -13
Main Therapeutic Indication : Anti-allergic
Currency : USD
2017 Revenue in Millions : 123
2016 Revenue in Millions : 125
Growth (%) : -2
LOOKING FOR A SUPPLIER?